Lenskart Solutions Limited (LENSKART)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Q2 FY27 revenue grew 32.5% y-y to ₹2,845 Cr; EBITDA up 46.6% to ₹624 Cr; PAT more than doubled to ₹232 Cr
- India revenue +35.3% y-y to ₹1,668 Cr; EBITDA margin expanded to 16%; 143 net new stores added
- International revenue +29.5% y-y to ₹1,201 Cr; EBITDA margin improved to 10.6%
- 80 lakh eye tests globally (+40% y-y); 3,624 stores worldwide; Hustlr ₹500 glasses gaining traction
- Hyderabad plant commissioning in ~12 months to boost automation and capacity
- AI-assisted eye test pilot live; potential to increase optometrist productivity 10x
- Smart glasses launched April 2026; available in 500 stores; focus on quality and software updates
- Long-term margin target 25% driven by owning full supply chain and technology integration
- Multiple analyst queries on margin trajectory and international growth; management confident on volume-led expansion
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 LENSKART — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add LENSKART to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Lenskart Solutions Limited
Important.
The summary above is generated automatically from Lenskart Solutions Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.